• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Modular Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    9/23/25 8:30:42 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care
    Get the next $MODD alert in real time by email
    false 0001074871 0001074871 2025-09-22 2025-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event Reported): September 22, 2025

     

    MODULAR MEDICAL, INC.

    (Exact Name of Registrant as Specified in Charter)

     

    001-41277 

    (Commission File Number)

     

    Nevada   87-0620495
    (State or Other Jurisdiction
    of Incorporation)
      (I.R.S. Employer
    Identification Number)

     

    10740 Thornmint Road

    San Diego, California 92127

    (Address of principal executive offices, with zip code)

     

    (858) 800-3500

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   MODD   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    As previously disclosed, in May 2023, Modular Medical, Inc. (the “Company”) entered into an underwriting agreement with Newbridge Securities Corporation (“Newbridge”) and issued, in connection with an underwritten offering, warrants to purchase 3,564,183 shares of the Company’s common stock (the “2023 Warrants”) with the 2023 Warrants having an exercise price of $1.22 per share.

     

    As previously disclosed, in March 2025, the Company issued, in connection with a private placement, warrants to purchase 6,508,073 shares of the Company’s common stock (the “2025 Warrants” and, together with the 2023 Warrants, the “Outstanding Warrants”) with the 2025 Warrants having an exercise price of $1.12 per share.

     

    On September 22, 2025, the Company entered into inducement offer letter agreements (the “2023 Inducement Letters”) with holders of the 2023 Warrants representing warrants to purchase 1,519,200 shares of the Company’s common stock. Pursuant to the 2023 Inducement Letters, the holders agreed to exercise these 2023 Warrants at an exercise price of $0.68 per share, an approximately ten percent (10%) discount to the $0.7611 Nasdaq Official Closing Price on September 19, 2025 (such reduced exercise price, the “New Exercise Price”).

     

    On September 22, 2025, the Company entered into inducement offer letter agreements (the “2025 Inducement Letters” and, together with the 2023 Inducement Letters, the “Warrant Letters”) with holders of the 2025 Warrants representing warrants to purchase 3,975,428 shares of the Company’s common stock. Pursuant to the 2025 Inducement Letters, the holders agreed to exercise these 2025 Warrants at the New Exercise Price. As a result of entering into the Warrant Letters, the Company will receive gross proceeds of approximately $3.7 million, before deducting expenses related to the Company entering into the Warrant Letters.

     

    In consideration for the holders of the Outstanding Warrants agreeing to enter into the Warrant Letters, the Company agreed to issue new warrants to purchase approximately 2,747,314 shares of the Company’s common stock (the “New Warrants”) (fifty percent (50%) of the Outstanding Warrants exercised pursuant to the Warrant Letters) with an exercise price of $0.84 per share (an approximately ten percent (10%) premium to the $0.7611 Nasdaq Official Closing Price on September 19, 2025). The transaction is expected to close on or about September 25, 2025 (the “Closing Date”).

     

    The New Warrants will be issued with a Securities Act of 1933, as amended (the “Securities Act”), restrictive legend and will be exercisable on the date of issuance and have a term of exercise of 5 years from the date of issuance. The Company will use commercially reasonable efforts to register the resale of the shares of the Company’s common stock underlying the New Warrants (the “New Warrant Shares”). There is no established trading market for the New Warrants, and the Company does not expect an active trading market to develop. The Company does not intend to apply to list the New Warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the New Warrants will be extremely limited.

     

    If, at the time a holder exercises its New Warrants, a registration statement registering the resale of the New Warrant Shares by the holder under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part), the net number of shares of Common Stock determined according to a formula set forth in the New Warrants.

     

    The Company expects to enter into further Warrant Letters prior to the Closing Date and will release additional disclosure as to the final amounts of Outstanding Warrants exercised and the number of New Warrants issued.

     

    Newbridge acted as the servicing agent (solely for informational and logistical purposes) with regard to the Warrant Letters and will receive a fixed fee of $400,000 and expense reimbursement of up to $50,000, regardless of the amount of gross proceeds that the Company receives from the exercise of the Outstanding Warrants.

     

    1

     

     

    The shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) issuable upon exercise of the 2023 Warrants have been registered pursuant to an existing registration statement on Form S-3 (File No. 333-271413), declared effective by the Securities and Exchange Commission (the “SEC”) on August 19, 2025.

     

    The resale of the shares of Common Stock underlying the 2025 Warrants exercised have been registered pursuant to an existing registration statement on Form S-3 (File No. 333-286768), declared effective by the SEC on May 7, 2025.

     

    The forms of the 2023 Inducement Letters, the 2025 Inducement Letters, and New Warrants are attached hereto as Exhibits 10.1, 10.2, and 4.1, respectively. The description of the terms of the Warrant Letters and the New Warrants is not intended to be complete and is qualified in its entirety by reference to such exhibits.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The Company issued the New Warrants in reliance on the exemption provided by Section 3(a)(9) of the Securities Act as involving an exchange by the Company exclusively with its security holders, Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated thereunder and in reliance on similar exemptions under applicable state laws with such reliance on Rule 506 based in part upon a representation of each of the holders of the Outstanding Warrants who signed Warrant Letters that they are an “accredited investor” as defined in Rule 501 promulgated pursuant to the Securities Act. Neither the issuance of the New Warrants nor the New Warrant Shares have been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. The description of the New Warrants under Item 1.01 of this Form 8-K is incorporated by reference herein.

     

    Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy the Company’s securities.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

     

    The following exhibits are filed with this report:

     

    Exhibit
    Number
      Exhibit Description
    4.1   Form of Common Stock Purchase Warrant
    10.1   Form of 2023 Inducement Letter
    10.2   Form of 2025 Inducement Letter
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      MODULAR MEDICAL, INC.
         
    Date: September 23, 2025 By:  /s/ James E. Besser
        James E. Besser
        Chief Executive Officer

     

     

    3

     

     

    Get the next $MODD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MODD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MODD
    SEC Filings

    View All

    Modular Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    9/23/25 8:30:42 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Modular Medical Inc.

    EFFECT - Modular Medical, Inc. (0001074871) (Filer)

    8/20/25 12:15:02 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form POS AM filed by Modular Medical Inc.

    POS AM - Modular Medical, Inc. (0001074871) (Filer)

    8/13/25 5:29:22 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Modular Medical Announces Licensing and Partnership Agreement With Nudge BG

    -Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, announced a licensing and partnership agreement with Nudge BG."We are very excited to partner with Modular Medical to bring the next g

    12/19/24 4:01:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces Conference Call to Provide Business Update

    SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will hold a conference call and webcast on Thursday, December 5, 2024, at 10:00 a.m. Eastern Time to provide a business update.Conference Call and Webcast InformationDate: December 5, 2024Time: 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time)Conference Call Number: 1-888-506-0062International Call Number: +1-973-528-0011Passcode: 494842Webcast: CLICK HEREFor those unable to

    12/3/24 8:00:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces Pricing of $8.2 Million Public Offering

    SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has priced an underwritten public offering (the "offering") of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including Manchester Explorer, L.P., which is the largest shareholder of the Company and is managed by Jeb Besser, Modular Medical's Chief Executive Officer. The shares of common stock are being sold at a price t

    11/21/24 9:15:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Manchester Management Co Llc bought $1,299,997 worth of shares (677,082 units at $1.92) (SEC Form 4)

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    3/24/25 9:34:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Director by Deputization Manchester Management Co Llc bought $35,236 worth of shares (21,000 units at $1.68) (SEC Form 4)

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    12/4/24 6:05:34 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Director by Deputization Manchester Management Co Llc bought $168,950 worth of shares (100,000 units at $1.69) (SEC Form 4)

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    11/29/24 10:00:09 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Goldberg Jeff D

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    10/3/25 6:21:17 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Vos Ellen O'Connor

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    10/2/25 8:34:55 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Sheibley Philip Brent

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    10/2/25 8:33:46 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Financials

    Live finance-specific insights

    View All

    Modular Medical Announces Conference Call to Provide Business Update

    SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will hold a conference call and webcast on Thursday, December 5, 2024, at 10:00 a.m. Eastern Time to provide a business update.Conference Call and Webcast InformationDate: December 5, 2024Time: 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time)Conference Call Number: 1-888-506-0062International Call Number: +1-973-528-0011Passcode: 494842Webcast: CLICK HEREFor those unable to

    12/3/24 8:00:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump

    SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.Conference Call and Webcast InformationDate: September 5, 2024Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Conference Call Number: 1-88

    9/4/24 6:57:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump

    MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States. With its comme

    9/4/24 4:30:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Leadership Updates

    Live Leadership Updates

    View All

    Modular Medical Announces Addition to the Russell Microcap(R) Index

    SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalizatio

    6/3/24 8:00:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces Diabetes Industry Veteran Duane DeSisto Will Join the Board of Directors

    SAN DIEGO, CA / ACCESSWIRE / July 6, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced the appointment of medical device industry leader Duane DeSisto to its board of directors. Mr. DeSisto was previously President, CEO and Director of Insulet Corporation, developers of the groundbreaking OmniPod Insulin Management System, before retiring in 2014."Duane brings more than 25 years of experience in the medical device industry and is a visionary business leader credited with the launch and transformatio

    7/6/23 8:30:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Appoints Kevin Schmid as Chief Operating Officer

    Schmid brings 40 years of experience in medical devices for drug delivery and diabetes management and a background in high-volume manufacturingSAN DIEGO, CA / ACCESSWIRE / July 26, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabete

    7/26/22 8:15:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Modular Medical Inc.

    SC 13G - Modular Medical, Inc. (0001074871) (Subject)

    3/1/24 3:48:41 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Modular Medical Inc. (Amendment)

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    2/21/24 5:20:18 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care